Revisto, an Austin, Texas-based AI-powered review solution for pharmaceutical marketing materials, has raised $4 million in seed funding.
Investors
The round was led by LiveOak Ventures, with participation from Eli Lilly and Company, Tau Ventures, and Arkin Digital Health. This investment brings Revisto's total funding to $6 million.
LiveOak Ventures is an early-stage venture capital firm based in Austin, Texas, specializing in technology and tech-enabled services. With $500M under management, the firm has led over 60 growth investments.
Revisto Use of Funds
The company will use the funding to expand its team and accelerate product development.
About Revisto
Revisto provides an AI-powered software platform designed to streamline the medical, legal, and regulatory (MLR) review process for pharmaceutical marketing materials. The company uses advanced artificial intelligence, proprietary pharmaceutical data, and real-time FDA guidelines to automate and optimize this traditionally manual and tedious process. Revisto's AI-powered review solution harnesses customers’ brand-specific data and real-time FDA 21 CFR regulations and guidelines to address the pain points in the MLR review process.
Funding Details
Company: Revisto, Inc.
Raised: $4.0M
Round: Seed Round
Funding Date: November 2024
Lead Investor: LiveOak Ventures
Additional Investors: Eli Lilly and Company, Tau Ventures, Arkin Digital Health
Company Website: https://www.revisto.com/
Software Category: Medical, Legal, and Regulatory (MLR) Review Solutions
Source: https://www.businesswire.com/news/home/20241118352875/en/